Colvin R B, Preffer F I
Department of Pathology, Massachusetts General Hospital, Boston.
Clin Lab Med. 1991 Sep;11(3):693-714.
The first monoclonal antibody (MAb) approved by the Food and Drug Administration (FDA) for therapeutic use, OKT3, is now a standard treatment for organ allograft rejection. This article reviews the interpretation of laboratory tests used to manage patients treated with MAb. Emphasis is placed on OKT3, with which the experience is also the greatest, although comparisons with other MAbs in clinical trials is also discussed.
首个获美国食品药品监督管理局（FDA）批准用于治疗的单克隆抗体（MAb）——OKT3，现已成为器官移植排斥反应的标准治疗药物。本文回顾了用于管理接受单克隆抗体治疗患者的实验室检测结果解读。重点介绍了OKT3，因为我们对其的经验也最为丰富，不过也讨论了在临床试验中与其他单克隆抗体的比较情况。
